Distinct markers in the blood of people with coeliac disease have been detected within a few hours of gluten being consumed.
The research, published in Science Advances, involved an international collaboration of the world’s leading coeliac disease experts.
The peer-reviewed study included the Walter and Eliza Hall Institute of Medical Research in Australia, University of Oslo in Norway, and in the US, Massachusetts General Hospital and University of Chicago.
Associate Professor Jason Tye-Din, head of coeliac research at the Institute and a gastroenterologist at The Royal Melbourne Hospital said work was now underway to explore the development of a simple blood test for coeliac disease.
“For the many people following a gluten-free diet without a formal diagnosis of coeliac disease, all that might be required is a blood test before, and four hours after, a small meal of gluten.
“This would be a dramatic improvement on the current approach, which requires people to actively consume gluten for at least several weeks before undergoing an invasive procedure to sample the small intestine,” Associate Professor Tye-Din said.
Coeliac disease affects approximately 1.4% of people globally, many of whom remain undiagnosed. Symptoms of the disease are caused by a damaging immune response to gluten. After consuming gluten, patients can experience reactions such as nausea, vomiting, abdominal pain and diarrhoea.
Dr Bob Anderson, a joint senior author of the paper and the Chief Scientific Officer of ImmusanT Inc., said the new findings could address an important medical need.
“For the first time we have described the inflammatory reaction that patients with coeliac disease experience in the immediate hours after they are exposed to gluten.
“The unpleasant symptoms associated with the disease are linked to an increase in inflammatory molecules in the bloodstream, such as interleukin-2 (IL-2), produced by T cells of the immune system. This response is similar to what happens when an infection is present, however for people with coeliac disease, gluten is the trigger.
“This information underpins a potential new approach to diagnosis that addresses the emerging medical need to identify patients without coeliac disease who may be better served by other treatments for their chronic symptoms,” Dr Anderson said.
Researchers at ImmusanT first discovered the immune markers while assessing blood samples during the Phase I trial of a potential coeliac therapy called Nexvax2. Gastrointestinal symptoms in patients injected with the gluten peptides, particularly nausea and vomiting, correlated with higher levels of IL-2 in their blood.
Subsequent testing showed the consumption of gluten produced the same IL-2 response in people with coeliac disease.
CEO of Coeliac Australia, Ms Michelle Laforest, said the finding would be welcome news for the coeliac community in Australia.
“The potential for a one-off gluten challenge and blood test could make a significant difference to many thousands of Australians who report sensitivity to gluten but have been unable to tolerate the current testing approach.
“It is clear this research has the potential to revolutionise the current testing regime for coeliac disease globally,” Ms Laforest said.
